Literature DB >> 28610760

Iatrogenic Kaposi's Sarcoma: a Retrospective Cohort Study in an Italian Tertiary Care Centre.

L Brambilla1, A Tourlaki1, G Genovese2.   

Abstract

AIMS: Kaposi's sarcoma (KS) is a lymphoangioproliferative multicentric disorder. Among its four distinct clinical variants, iatrogenic KS (iKS) typically affects patients who have received immunosuppressant regimens for organ transplants, proliferative disorders, or immune-mediated diseases. The aim of the current study was to examine the characteristics of a cohort of patients with iKS, evaluating the differences in terms of epidemiological and clinical features, management and outcomes between organ transplant recipients (OTR) and patients immunosuppressed for other medical conditions.
MATERIALS AND METHODS: This retrospective study included, out of 1389 KS patients, 143 patients suffering from iKS being followed in an Italian tertiary care centre from November 1995 to December 2016. Demographic data, clinical features, previous immunosuppressive therapies, management, and outcomes were recorded for each patient.
RESULTS: We detected iKS in 10.3% of the analysed KS population. The mean age was 71.9 years in non-OTR versus 51.4 years in OTR (P = 0.04). Staging at diagnosis showed a more severe disease in non-OTR than in OTR, with stage IA observed in 33.3% of OTR versus 11.8% of non-OTR (P < 0.001) and stage IVB in 29.1% of non-OTR versus 12.1% of OTR (P = 0.001). Corticosteroids represented the most frequent immunosuppressive drugs at diagnosis in both groups, in conjunction with cyclosporine A in OTR. Immunosuppressant reduction or withdrawal was carried out in 93.9% of OTR versus 63.6% of non-OTR (P < 0.001).
CONCLUSIONS: As corticosteroids and cyclosporine A are the most common iKS-inducing drugs, their reduction or withdrawal, wherever possible, is needed. Differences in disease severity at presentation between OTR and non-OTR may interfere with the choice of management strategy and the consequent outcome.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Kaposi's sarcoma; iatrogenic; organ transplant

Mesh:

Year:  2017        PMID: 28610760     DOI: 10.1016/j.clon.2017.05.008

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.

Authors:  Shamir Geller; Mark A Dickson; Klaus J Busam; Patricia L Myskowski
Journal:  J Oncol Pract       Date:  2018-07-25       Impact factor: 3.840

2.  Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma.

Authors:  Louise Pesqué; Julie Delyon; Coralie Lheure; Barouyr Baroudjian; Maxime Battistella; Pascal Merlet; Céleste Lebbé; Laetitia Vercellino
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

3.  Comparative transcriptome analysis of endemic and epidemic Kaposi's sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis.

Authors:  Salum J Lidenge; Andrew V Kossenkov; For Yue Tso; Jayamanna Wickramasinghe; Sara R Privatt; Owen Ngalamika; John R Ngowi; Julius Mwaiselage; Paul M Lieberman; John T West; Charles Wood
Journal:  PLoS Pathog       Date:  2020-07-24       Impact factor: 6.823

4.  The Spectrum of Underlying Causes of Iatrogenic Kaposi's Sarcoma in a Large Series: A Retrospective Study.

Authors:  Can Baykal; Tugba Atci; Nesimi Buyukbabani; Armagan Kutlay
Journal:  Indian J Dermatol       Date:  2019 Sep-Oct       Impact factor: 1.494

Review 5.  Imaging of Kaposi sarcoma.

Authors:  Dhivya Addula; Chandan J Das; Vikas Kundra
Journal:  Abdom Radiol (NY)       Date:  2021-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.